Stability-Indicating Methods beyond Forced Degradation: A Comprehensive Review

Abstract

Background: Stability-indicating methods (SIMs) constitute a critical component of pharmaceutical quality assurance, enabling the accurate quantification of active pharmaceutical ingredients (APIs) in the presence of degradation products generated under storage conditions. While forced degradation studies have historically formed the foundation of SIM development, contemporary regulatory expectations and scientific advances necessitate a more comprehensive, integrated approach to stability evaluation. Objective: This review systematically examines the current state of SIM science, encompassing forced degradation studies, real-time and accelerated stability testing under ICH Q1A(R2), photostability assessment per ICH Q1B, humidity cycling effects, and advanced analytical detection strategies. Scope: Key topics addressed include the validation requirements of ICH Q2(R1), Arrhenius-based kinetic modeling, Quality by Design (QbD) frameworks, liquid chromatography-mass spectrometry characterization, and emerging applications of machine learning to stability datasets. Three illustrative case studies demonstrate integrated stability strategy implementation: a hygroscopic antibiotic formulation, a photolabile antitumor agent, and a multi-component fixed-dose combination. Conclusion: No single testing paradigm is sufficient to characterize pharmaceutical stability comprehensively. An integrated strategy combining real-time monitoring, kinetic modeling, photostability testing, humidity cycling studies, and predictive analytics provides the most robust and regulatory-compliant evidence base for shelf-life determination throughout the drug development lifecycle.